[go: up one dir, main page]

MX2022007624A - Combinaciones. - Google Patents

Combinaciones.

Info

Publication number
MX2022007624A
MX2022007624A MX2022007624A MX2022007624A MX2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A MX 2022007624 A MX2022007624 A MX 2022007624A
Authority
MX
Mexico
Prior art keywords
combinations
disease
treating
compounds
condition
Prior art date
Application number
MX2022007624A
Other languages
English (en)
Inventor
Kevin Duane Bunker
Fernando Donate
Peter Qinhua Huang
Ahmed Abdi Samatar
Jiali Li
Jianhui Ma
Sayee Gajanan Hegde
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of MX2022007624A publication Critical patent/MX2022007624A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Glass Compositions (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)

Abstract

En la presente descripción se describen combinaciones de compuestos para tratar una enfermedad o afección, tal como el cáncer. Una combinación de compuestos para tratar una enfermedad o afección puede incluir un inhibidor de SERD y un inhibidor de WEE1, junto con sales farmacéuticamente aceptables de cualquiera de los anteriores.
MX2022007624A 2019-12-20 2020-12-16 Combinaciones. MX2022007624A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962952042P 2019-12-20 2019-12-20
US202063009754P 2020-04-14 2020-04-14
PCT/US2020/065411 WO2021127046A1 (en) 2019-12-20 2020-12-16 Combinations

Publications (1)

Publication Number Publication Date
MX2022007624A true MX2022007624A (es) 2022-08-16

Family

ID=76478099

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007624A MX2022007624A (es) 2019-12-20 2020-12-16 Combinaciones.

Country Status (12)

Country Link
US (1) US20230042653A1 (es)
EP (1) EP4069224A4 (es)
JP (1) JP2023507799A (es)
KR (1) KR20220119428A (es)
CN (1) CN115103673A (es)
AU (1) AU2020408698A1 (es)
BR (1) BR112022012286A2 (es)
CA (1) CA3165477A1 (es)
IL (1) IL294084A (es)
MX (1) MX2022007624A (es)
TW (1) TW202135810A (es)
WO (1) WO2021127046A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008133866A1 (en) * 2007-04-25 2008-11-06 Merck & Co., Inc. Polymorph of dihydropyrazolopyrimidinone derivative as weel kinase.inhibitor
CA2706946A1 (en) * 2007-11-28 2009-06-04 Schering Corporation 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
PT2477628E (pt) * 2009-09-15 2014-11-25 Merck Sharp & Dohme Preparação de formas de hemihidrato cristalino de dihidropirazolopirimidinona
SI2925888T1 (en) * 2012-11-28 2018-02-28 Merck Sharp & Dohme Corp. Compounds and methods for the treatment of cancer
WO2016146591A1 (en) * 2015-03-16 2016-09-22 Astrazeneca Ab Combination treatment
US10947238B2 (en) * 2015-11-01 2021-03-16 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of making and using the same
AU2017242027B2 (en) * 2016-04-01 2020-10-08 Recurium Ip Holdings, Llc Estrogen receptor modulators
WO2018209239A1 (en) * 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN111344290B (zh) * 2017-11-01 2023-12-01 无锡智康弘义生物科技有限公司 作为Wee1抑制剂的大环类化合物及其应用
BR112022002138A2 (pt) * 2019-08-06 2022-04-19 Recurium Ip Holdings Llc Moduladores do receptor de estrogênio para tratamento de mutantes

Also Published As

Publication number Publication date
EP4069224A4 (en) 2023-12-20
BR112022012286A2 (pt) 2022-08-30
CA3165477A1 (en) 2021-06-24
WO2021127046A1 (en) 2021-06-24
IL294084A (en) 2022-08-01
US20230042653A1 (en) 2023-02-09
KR20220119428A (ko) 2022-08-29
CN115103673A (zh) 2022-09-23
TW202135810A (zh) 2021-10-01
AU2020408698A1 (en) 2022-07-14
JP2023507799A (ja) 2023-02-27
EP4069224A1 (en) 2022-10-12

Similar Documents

Publication Publication Date Title
MX2022007628A (es) Combinaciones.
MX2022007626A (es) Combinaciones.
MX2023008954A (es) Inhibidores de los receptores erbb.
NZ790037A (en) Combinations
MX2021005075A (es) Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion.
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
EA202193015A1 (ru) Ингибиторы cdk
PH12021552482A1 (en) Compounds targeting prmt5
WO2019169065A3 (en) Wee1 kinase inhibitors and methods of treating cancer using the same
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
CR20240296A (es) Inhibidores parp1
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
GEAP202415883A (en) Macrocyclic compounds as sting agonists and methods and uses thereof
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
HK1254954A1 (zh) Lpt-723和免疫检查点抑制剂组合物及其治疗方法
MX2020008678A (es) Metodos de uso para derivados de benzotriazol trisustituidos.
MX2021010321A (es) Compuestos macrociclicos.
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
PH12017501882A1 (en) Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor
PH12021552953A1 (en) Tricyclic compounds
WO2018005444A3 (en) Methods for treating cancer
NZ790033A (en) Combinations
MX2021000935A (es) Composiciones y metodos terapeuticos para el tratamiento de cancer pancreatico con acido 6,8-bis(bencilsulfanil)octanoico.
MX2023005530A (es) Metodos y composiciones que comprenden un inhibidor de krasg12c y un antagonista de union a pd-l1 para tratar cancer de pulmon.
EP3970793A4 (en) MEANS OF PREVENTING, IMPROVING OR TREATMENT OF PERIODONTAL DISEASES